Chief Science Officer


Dr. Khursheed Anwer to


D


eliver


V


irtual


P


resentation


Monday, October 18 at 7:30 a.m. Eastern Time

LAWRENCEVILLE, N.J., Oct. 15, 2021 (GLOBE NEWSWIRE) —


Celsion Corporation (NASDAQ: CLSN),

a clinical-stage development company focused on DNA mediated immunotherapy and next-generation nucleic vaccines, announces that a time of Monday, October 18, 2021 at 7:30 a.m. Eastern time has been set for Khursheed Anwer, Ph.D., executive vice president and chief science officer, to deliver his presentation at the International Vaccines Congress. A link to Dr. Anwer’s presentation, titled “Immunogenicity of DNA Vaccines based on Multicistronic Vectors and Synthetic DNA Delivery Systems,” will be available on Celsion’s website at that time and can be viewed

here

.

The virtual conference is being held October 18-19, 2021.

About the PLACCINE


P


latform

PLACCINE is Celsion’s proprietary plasmid and DNA delivery technology and the subject of a provisional patent application that covers a broad range of next-generation DNA vaccines. An adaptation of the Company’s TheraPlas technology, PLACCINE is a DNA vaccine technology platform characterized by a single plasmid DNA with multiple coding regions. The plasmid vector is designed to express multiple pathogen antigens along with a potent immune modifier. It is delivered via a synthetic delivery system and has the potential to be easily modified to create vaccines against a multitude of infectious diseases, addressing:

• 
  Viral Mutations
  
  : PLACCINE may offer broad-spectrum and mutational resistance (variants) by targeting multiple antigens on a single plasmid vector.
• 
  Enhanced Efficacy
  
  : The potent immune modifiers such as cytokines and chemokines may improve humoral and cellular responses to viral antigens and can be incorporated in the plasmid.
• 
  Durable Efficacy
  
  : PLACCINE delivers a DNA plasmid-based antigen that can result in durable antigen exposure and a robust vaccine response to viral antigens.
• 
  Storage & Distribution
  
  : PLACCINE allows for stability that is compatible with manageable vaccine storage and distribution.
• 
  Dosing & Administration
  
  : PLACCINE is a synthetic delivery system that should require a simple injection that does not require viruses or special equipment to deliver its payload.

About Celsion


Corporation

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies, DNA-based therapies and directed chemotherapies through clinical trials and eventual commercialization. The company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit

www.celsion.com

.

Forward-looking Statements

Forward-looking


statements


in


this


news


release


are


made


pursuant


to


the


“safe


harbor”


provisions


of


the


Private


Securities


Litigation


Reform


Act


of 1995.


These


statements


are


based


upon


current


beliefs,


expectation,


and


assumptions


and


include


statements


regarding


the


platform


having


the


potential


to


provide


broad


protection


against


coronavirus


disease


2019


(COVID-19),


and


possible


future


mutations


of


SARS-CoV-2


or


other


coronaviruses.


These


statements


are


subject


to


a


number


of


risks


and


uncertainties,


many


of


which


are


difficult


to


predict,


including


the


ability


of


the


Company’s


platform


to


provide


broad


protection


against


COVID-19,


and


possible


future


mutations


of


SARS-CoV-2


or


other


coronaviruses,


the


issuance


of


a


patent


to


the


Company


for


use


of


its


technology


platform


for


treating


or


preventing


infection


with


the


SARS-CoV-2


virus


that


causes


COVID-19,


unforeseen


changes


in


the


course


of


research


and


development


activities


and


in


clinical


trials;


the


uncertainties


of


and


difficulties


in


analyzing


interim


clinical


data,


particularly


in


small


subgroups


that


are


not


statistically


significant;


FDA


and


regulatory


uncertainties


and


risks;


the


significant


expense,


time


and


risk


of


failure


of


conducting


clinical


trials;


the


need


for


Celsion


to


evaluate


its


future


development


plans;


possible acquisitions


or


licenses


of


other


technologies,


assets


or


businesses;


possible


actions


by


customers,


suppliers,


competitors


or


regulatory


authorities;


and


other


risks


detailed


from


time


to


time


in


the


Celsion’s


periodic


filings


with


the


Securities


and


Exchange


Commission.


Celsion


assumes


no


obligation to update


or supplement


forward-looking


statements that


become untrue because


of


subsequent events,


new


information


or


otherwise.

CONTACTS:

Celsion Corporation


Jeffrey W. Church

Executive Vice President and CFO

609-482-2455



[email protected]

LHA Investor Relations


Kim Sutton Golodetz 212-838-3777



[email protected]

# # #